Skip to main content

Table 3 Genes differentially expressed between metaplastic breast cancer subtypes

From: Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes

Gene Log2 Fold Change p-value FDR-adjusted p-value
Genes differentially expressed in Mesenchymal vs. all other MpBC types
 AQP5 10.36 < 2.22E-16 < 2.22E-16
 IL1A −3.83 1.36E-11 2.28E-09
 EXTL1 9.07 6.84E-11 7.67E-09
 TNFRSF11B 5.02 1.36E-09 1.14E-07
 FGFBP2 6.91 2.22E-08 1.49E-06
 PSG5 −6.16 2.84E-08 1.59E-06
 CXCL5 −2.49 1.34E-07 6.43E-06
 CA6 21.62 2.11E-05 8.85E-04
 CCL2 −3.10 2.39E-05 8.92E-04
 IRF1 −2.48 8.46E-05 2.84E-03
 IFI35 −2.20 1.23E-04 3.76E-03
 STAT1 −1.98 4.09E-04 1.15E-02
 TYMP −2.00 5.00E-04 1.29E-02
 EPSTI1 −2.51 6.65E-04 1.40E-02
 ICAM1 −2.42 6.29E-04 1.40E-02
 OAS3 −1.65 6.67E-04 1.40E-02
 BST2 −2.30 7.25E-04 1.43E-02
 ARC 2.43 9.32E-04 1.74E-02
 TAP1 −2.19 1.02E-03 1.81E-02
 SAMHD1 −1.76 2.34E-03 3.93E-02
 SYNGR1 1.30 2.82E-03 4.31E-02
 TNFRSF10B −1.47 2.76E-03 4.31E-02
 CXCL11 −2.64 3.29E-03 4.60E-02
 STC1 −2.23 3.21E-03 4.60E-02
Genes differentially expressed in Spindle cell vs. all other MpBC types
 SPRR1A −5.30 6.48E-13 2.18E-10
 SPRR2A −3.67 3.28E-12 5.51E-10
 SPRR2D −22.62 8.87E-12 9.94E-10
 AQP5 5.73 3.26E-11 2.74E-09
 EXTL1 2.98 6.86E-11 4.61E-09
 CXCL6 6.08 2.27E-09 1.27E-07
 LY6D −1.56 2.75E-09 1.32E-07
 KRT4 −2.64 9.36E-09 3.93E-07
 TFPI2 2.98 1.17E-08 4.37E-07
 CXCL5 3.10 1.61E-07 5.41E-06
 NEFM 5.58 2.92E-05 8.92E-04
 IL1B 2.65 7.61E-05 2.13E-03
 MAOB 2.57 2.80E-04 7.25E-03
 FN1 1.66 4.80E-04 1.04E-02
 CCL2 1.53 4.94E-04 1.04E-02
 LEP −21.29 4.51E-04 1.04E-02
 MMP9 2.92 5.87E-04 1.16E-02
 CXCL3 2.07 9.76E-04 1.64E-02
 HSPA6 1.31 9.46E-04 1.64E-02
 VIPR1 −2.30 9.44E-04 1.64E-02
 ROR1 1.08 2.21E-03 3.53E-02
 OXTR 1.66 2.39E-03 3.65E-02
 TNFRSF10D 1.62 2.60E-03 3.80E-02
 DKK1 2.42 3.30E-03 4.62E-02
Genes differentially expressed in Squamous vs. all other MpBC types
 AQP5 −24.83 < 2.22E-16 < 2.22E-16
 ELF5 −2.79 < 2.22E-16 < 2.22E-16
 SPRR1A 6.65 3.37E-12 3.77E-10
 SPRR2A 6.30 4.54E-12 3.81E-10
 TF −3.00 1.90E-11 1.28E-09
 HSP90AA4P −2.99 4.67E-11 2.62E-09
 CA6 −8.88 1.43E-10 6.87E-09
 EXTL1 −19.35 2.62E-10 1.10E-08
 PSG5 0.20 1.83E-09 6.84E-08
 GLYATL2 3.00 7.10E-09 2.39E-07
 PI3 5.49 7.14E-08 2.18E-06
 TCN1 3.97 3.25E-05 8.59E-04
 EPGN 2.68 3.32E-05 8.59E-04
 DHRS9 2.21 7.43E-05 1.78E-03
 SPRR2D 11.54 1.09E-04 2.44E-03
 SLC47A2 4.33 1.52E-04 3.19E-03
 DSCAM −23.49 1.79E-04 3.53E-03
 ID4 −2.93 2.20E-04 4.11E-03
 ALDH3B2 3.18 2.89E-04 5.12E-03
 CITED1 3.80 3.23E-04 5.43E-03
 EEF1A2 3.03 4.19E-04 6.40E-03
 CCL20 2.22 4.13E-04 6.40E-03
 C12orf39 2.70 5.40E-04 7.89E-03
 STEAP4 2.28 6.83E-04 9.56E-03
 PPL 2.03 7.28E-04 9.79E-03
 NEFM −5.96 9.26E-04 1.20E-02
 HAS2 −2.14 1.18E-03 1.47E-02
 LCE3D 4.05 1.26E-03 1.52E-02
 CDRT1 2.92 1.60E-03 1.85E-02
 PTHLH 2.48 1.74E-03 1.88E-02
 PRSS22 1.99 1.72E-03 1.88E-02
 ALDH1A1 1.67 2.01E-03 2.11E-02
 TNFAIP2 1.41 2.30E-03 2.35E-02
 LEP 8.40 2.94E-03 2.91E-02
 ELF3 2.34 4.25E-03 4.08E-02
 GRHL3 2.08 4.82E-03 4.50E-02
  1. MpBC metaplastic breast cancer. FDR: false discovery rate